4.8 Article

Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations

期刊

NATURE MEDICINE
卷 20, 期 12, 页码 1410-1416

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/nm.3746

关键词

-

资金

  1. Bundesministerium fur Bildung und Forschung, grant: Integriertes Forschungs und Behandlungszentrum/Center for Chronic Immunodeficiencies [01EO1303]
  2. Bildung und Forschung, grant Systems Biology E:med/SysInflame [012X1306F]
  3. Deutsches Zentrum fur Infelctionsforschung [8000805-3]
  4. Excellence Initiative of the German Research Foundation [GSC-4]
  5. Intramural Research Program of the US National Institutes of Health, National Library of Medicine
  6. DFG [CRC 992]
  7. UK Medical Research Council
  8. Wellcome Trust
  9. Diabetes UK
  10. Japan Society for the Promotion of ScienceYoung Scientist B grant
  11. Ministry of Education, Culture, Sports, Science and Technology of Japan
  12. Japan Science and Technology Agency
  13. Biotechnology and Biological Sciences Research Council [BB/H013598/1, BB/H013598/2] Funding Source: researchfish
  14. Diabetes UK [12/0004477] Funding Source: researchfish
  15. Medical Research Council [G0802382] Funding Source: researchfish
  16. BBSRC [BB/H013598/2, BB/H013598/1] Funding Source: UKRI
  17. MRC [G0802382] Funding Source: UKRI
  18. Grants-in-Aid for Scientific Research [25440031, 25860356] Funding Source: KAKEN

向作者/读者索取更多资源

The protein cytotoxic T lymphocyte antigen-4 (CTLA-4) is an essential negative regulator of immune responses, and its loss causes fatal autoimmunity in mice. We studied a large family in which five individuals presented with a complex, autosomal dominant immune dysregulation syndrome characterized by hypogammaglobulinemia, recurrent infections and multiple autoimmune clinical features. We identified a heterozygous nonsense mutation in exon 1 of CTLA4. Screening of 71 unrelated patients with comparable clinical phenotypes identified five additional families (nine individuals) with previously undescribed splice site and missense mutations in CTLA4. Clinical penetrance was incomplete (eight adults of a total of 19 genetically proven CTLA4 mutation carriers were considered unaffected). However, CTLA-4 protein expression was decreased in regulatory T cells (T-reg cells) in both patients and carriers with CTLA4 mutations. Whereas T-reg cells were generally present at elevated numbers in these individuals, their suppressive function, CTLA-4 ligand binding and transendocytosis of CD80 were impaired. Mutations in CTLA4 were also associated with decreased circulating B cell numbers. Taken together, mutations in CTLA4 resulting in CTLA-4 haploinsufficiency or impaired ligand binding result in disrupted T and B cell homeostasis and a complex immune dysregulation syndrome.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据